2024-513271-41-00招募中2 期
A phase 1/2 study exploring the safety and activity of Trifluridine/Tipiracil in combination with Capecitabine and Bevacizumab in metastatic colorectal cancer patients. The TriComB trial
Gruppo Oncologico Del Nord Ovest, Gruppo Oncologico Del Nord Ovest16 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2024年9月16日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 36
- 试验地点
- 16
- 主要终点
- Objective Response Rate (ORR) is defined as the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria, determined by investigator reported measurements. According to RECIST 1.1 criteria and the non-randomised nature of the study, a confirmation of CR and PR is required.
研究概览
简要总结
To evaluate the activity of the combination (trifluridine/tipiracil plus capecitabine plus bevacizumab) in previously untreated mCRC patients deemed unfit for intensive chemotherapy in terms of Objective Response Rate (ORR) per RECIST v1.1.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Written informed consent to study procedures.
- •Neutrophils =1.5 x 109/L, Platelets =100 x 109/L, Hemoglobin = 9 g/dl
- •Total bilirubin =1.5 fold the upper-normal limits (UNL), AST (SGOT) and/or ALT (SGPT) = 2.5 x UNL (or <5 x UNL in the case of liver metastases), alkaline phosphatase = 2.5 x UNL (or <5 x UNL in case of liver metastases)
- •Creatinine clearance = 50 mL/min or serum creatinine =1.5 x UNL
- •Male subjects with female partners of childbearing potential must be willing to use adequate contraception as approved by the investigator (barrier contraceptive measure or oral contraception)
- •Women of childbearing potential must have a negative blood pregnancy test at the baseline visit. For this trial, women of childbearing potential are defined as all women after puberty, unless they are postmenopausal for at least 12 months, are surgically sterile, or are sexually inactive. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. A high follicle stimulating hormone (FSH) level in the postmenopausal range may be used to confirm a post-menopausal state in women not using hormonal contraception or hormonal replacement therapy. However in the absence of 12 months of amenorrhea, a single FSH measurement is insufficient.
- •Subjects and their partners must be willing to avoid pregnancy during the trial and until 6 months after the last trial treatment.
- •Will and ability to comply with the protocol.
- •Histologically proven diagnosis of colorectal cancer.
- •Metastatic colorectal cancer not previously treated with chemotherapy for metastatic disease.
- •At least one measurable lesion according to RECIST1.
- •Age = 18 years.
- •ECOG PS = 1
- •Life expectancy of at least 12 weeks.
- •Availability of archival tumour tissue (primary tumour and metastases or at least one of the two) for biomarker analysis
- •Previously not eligible for a chemotherapy doublet or triplet (oxaliplatin and/or irinotecan-based combination)
排除标准
- •Radiotherapy to any site within 4 weeks before the study.
- •Significant vascular disease (e.g. aortic aneurysm requiring surgical repair or recent arterial thrombosis) within 6 months of study enrolment.
- •Any previous venous thromboembolism = NCI CTCAE Grade
- •History of abdominal fistula, GI perforation, intra-abdominal abscess or active GI bleeding within 6 months prior to the first study treatment.
- •Treatment with any investigational drug within 30 days prior to enrolment or 2 investigational agent half-lives (whichever is longer).
- •Other co-existing malignancies or malignancies diagnosed within the last 5 years with the exception of localized basal and squamous cell carcinoma or cervical cancer in situ.
- •Lack of physical integrity of the upper gastrointestinal tract, malabsorption syndrome, or inability to take oral medication.
- •Known hypersensitivity to trial drugs or hypersensitivity to any other component of the trial drugs.
- •Any concomitant drugs contraindicated for use with the trial drugs according to the product information of the pharmaceutical companies.
- •Pregnant or lactating women. Women of childbearing potential with either a positive or no pregnancy test at baseline. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential. Sexually active males and females (of childbearing potential) unwilling to practice contraception (barrier contraceptive measure or oral contraception) during the study and until 6 months after the last trial treatment.
- •Previous treatment with trifluridine/tipiracil, bevacizumab and capecitabine (previous • treatment with capecitabine was permitted only in the adjuvant setting and if more than 12 months elapsed between the end of adjuvant and first relapse).
- •Untreated brain metastases or spinal cord compression or primary brain tumors.
- •History or evidence upon physical examination of CNS disease unless adequately treated.
- •Clinical signs of malnutrition.
- •Active uncontrolled infections or other clinically relevant concomitant illness contraindicating chemotherapy administration.
- •Evidence of bleeding diathesis or coagulopathy
- •Uncontrolled hypertension and prior history of hypertensive crisis or hypertensive encephalopathy.
- •Clinically significant (i.e. active) cardiovascular disease for example cerebrovascular accidents (=6 months), myocardial infarction (=6 months), unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, serious cardiac arrhythmia equiring medication.
结局指标
主要结局
Objective Response Rate (ORR) is defined as the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria, determined by investigator reported measurements. According to RECIST 1.1 criteria and the non-randomised nature of the study, a confirmation of CR and PR is required.
Objective Response Rate (ORR) is defined as the percentage of patients, relative to the total of enrolled subjects, achieving a complete (CR) or partial (PR) response, according to RECIST 1.1 criteria, determined by investigator reported measurements. According to RECIST 1.1 criteria and the non-randomised nature of the study, a confirmation of CR and PR is required.
次要结局
- Overall Toxicity Rate is defined as the percentage of patients, relative to the total of enrolled subjects, experiencing any adverse event, according to National Cancer Institute Common Toxicity Criteria (version 5.0)
- Toxicity Rate is defined as the percentage of patients, relative to the total of enrolled subjects, experiencing a specific adverse event of grade 3/4, according to National Cancer Institute Common Toxicity Criteria (version 5.0).
- Progression Free Survival (PFS)
- Overall Survival (OS)
- The analysis of PROs endpoints
研究者
Chiara Cremolini
Scientific
Gruppo Oncologico Del Nord Ovest
研究点 (16)
Loading locations...
相似试验
招募中
3 期
ENGIC 06 (PRODIGE 114) – FFCD 2401 – FRUQUITAS
Randomized phase III trial to compare trifluridine/tipiracil + Fruquintinib versus trifluridine/tipiracil alone for metastatic oeso-gastric adenocarcinoma.2025-522395-92-00Fondation Franc.Cancerologie Digestive284
尚未招募
2 期
Trifluridine/Tipiracil Plus Fruquintinib vs. Trifluridine/Tipiracil Plus Bevacizumab in Refractory Metastatic Colorectal Cancer: A Randomized, Controlled, Open-Label, Non-Inferiority TrialNCT07261709Sun Yat-sen University236
招募中
3 期
Phase III study in first-line treatment of patients with metastatic colorectal cancer who are not candidate for intensive therapy. (SOLSTICE)2024-516180-85-00Institut De Recherches Internationales Servier IRIS84
已完成
2 期
Phase II, Open-Label Study of preliminary efficacy of Sitravatinib in Combination with Tislelizumab in Patients with Metastatic Uveal Melanoma with liver metastases.2024-519451-29-00Grupo Espanol Multidisciplinar De Melanoma16
招募中
2 期
Neoadjuvant Cemiplimab Plus Imiquimod in Cutaneous Basal Cell Carcinoma.2025-520698-38-00Instituto Oncologico Dr. Rosell S.L.18